WHO ICTRP trial
A randomized phase II study of Erlotinib with or without Bevacizumab in NSCLC…
JPRN-UMIN000007475 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000007475 |
|---|---|
| Public title | A randomized phase II study of Erlotinib with or without Bevacizumab in NSCLC patients previouly treated with platinum-based chemotherapy containing bevacizumab. North Japan Lung Cancer Study Group Trial 1201 |
| Scientific title | A randomized phase II study of Erlotinib with or without Bevacizumab in NSCLC patients previouly treated with platinum-based chemotherapy containing bevacizumab. North Japan Lung Cancer Study Group Trial 1201 - Randomized phase II study of 2nd line Erlotinib with or without Bevacizumab (NJLCG1201) |
| Primary sponsor | North Japan Lung Cancer Study Group |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase II |
| Countries | Japan |
| Conditions | non-squamous non-small cell lung cancer |
| Interventions | Erlotinib Erlotinib + Bevacizumab |
| Registration date | Sep 3, 2012 |
| Target size | 64 |
| Secondary IDs | NJLCG1201 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: